ATHENEX INC. news, videos and press releases
For more news please use our advanced search feature.
ATHENEX INC. - More news...
ATHENEX INC. - More news...
- Athenex, Inc. Reaches Agreement With Lenders to Pursue Expedited Sales Process
- Athenex Provides Fourth Quarter and Full Year 2022 Financial Results and Business Update
- Athenex Announces a Reverse Stock Split
- Athenex Announces MHRA Decision on Oral Paclitaxel
- Athenex Announces Quantum Leap Healthcare Collaborative Reports Positive Trial Result of I-SPY2 Trial for Oral Paclitaxel in Combination with PD-1 and Carboplatin in Neoadjuvant Breast Cancer
- Athenex Exits 503B Sterile Compounding Business
- Athenex Announces Positive Results of Special Stockholder Meeting
- Athenex Announces Closing of the Sale of its China API Business
- Athenex to Participate in the 5th Annual Evercore ISI HealthCONx Conference
- Athenex Announces Receipt of Positive Nasdaq Listing Determination
- Athenex to Provide Corporate and Financial Update for the Third Quarter 2022 on November 3, 2022
- Athenex Files Definitive Proxy Statement for Special Stockholder Meeting
- Athenex to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
- Athenex, Inc. Announces Pricing of $30 Million Public Offering of Common Stock and Warrants
- Athenex, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Warrants
- Athenex Provides Second Quarter 2022 Financial Results and Business Update
- Athenex Announces Publication of Data from Phase 3 Study Comparing Oral Paclitaxel Plus Encequidar Versus Intravenous Paclitaxel in Patients with Metastatic Breast Cancer in the Journal of Clinical Oncology
- Athenex to Provide Corporate and Financial Update for the Second Quarter 2022 on July 28, 2022
- Athenex Announces Entry into Agreement to Sell its China API Business to TiHe Capital (Bejing) Co., Ltd.
- Athenex to Participate in Truist Securities Cell Therapy Symposium
- Athenex Announces Sale of Revenues from U.S. and European Royalty and Milestone Interests in Klisyri® (tirbanibulin) to Sagard Healthcare Partners and Oaktree
- Athenex Announces Clinical Collaboration with Merck to Evaluate Oraxol plus KEYTRUDA® (pembrolizumab) in Patients with Non-Small Cell Lung Cancer (NSCLC)
- Athenex Provides First Quarter 2022 Financial Results and Business Update
- Athenex, Texas Children’s Cancer Center, and the Center for Cell and Gene Therapy at Baylor College of Medicine to Present Phase 1 Clinical Data for KUR-501, an autologous GD2 CAR-NKT Cell Therapy for Relapsed/Refractory High Risk Neuroblastoma at the ASGCT 25th Annual Meeting
- Athenex to Provide Corporate and Financial Update for the First Quarter 2022 on May 10, 2022
- Athenex Presents Interim Data from Phase 1 ANCHOR Study of KUR-502 (Allogeneic CD19 CAR-NKT Cells) in Relapsed or Refractory Lymphoma and Leukemia at the 2022 Transplantation & Cellular (“Tandem”) Meetings of ASTCT and CIBMTR
- Athenex Provides Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
- CORRECTION: Athenex to Provide Corporate and Financial Update for the Fourth Quarter and Full Year 2021, on March 16, 2022
- Athenex to Provide Corporate and Financial Update for the Fourth Quarter and Full Year 2021, on March 15, 2022
- Athenex Announces Appointment of Chief Financial Officer
